Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Johnson and Johnson
Express Scripts
Moodys
Medtronic

Last Updated: December 6, 2019

DrugPatentWatch Database Preview

Litigation Details for Elan Corporation v. Andrx Pharmaceutical (S.D. Fla. 1998)

See Plans and Pricing

« Back to Dashboard

Elan Corporation v. Andrx Pharmaceutical (S.D. Fla. 1998)

Docket   Start Trial Date Filed 1998-10-23
Court District Court, S.D. Florida Date Terminated 2009-03-11
Cause 35:0271 Patent Infringement Assigned To Adalberto Jose Jordan
Jury Demand None Referred To
Parties ANDRX PHARMACEUTICALS, INC.; ELAN CORPORATION, PLC
Patents 3,998,966; 5,637,320
Attorneys Alan B. Clement; Charles A. Weiss; Gerald J. Houlihan; Harvey W. Gurland , Jr.; James Costigan; James R. Barney; Martin P. Endres; Michael J. Flibbert; Michael T. Landen; Philip J. McCabe; Steven Ira Peretz; Terri Ellen Tuchman Meyers; Walter W. Brown
Link to Docket External link to docket
Small Molecule Drugs cited in Elan Corporation v. Andrx Pharmaceutical
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .

Details for Elan Corporation v. Andrx Pharmaceutical (S.D. Fla. 1998)

Date Filed Document No. Description Snippet Link To Document
1998-10-23 1 FOR PATENT |NFR|NGEMENT 4. United States Letters Patent No. 5,637,320 ("the '320 patent"…320 patent is attached hereto as Exhibit A. 5. Plaintiff Elan is the owner of the '320 patent. 6…expiration of the '320 patent was an act of infringement of the '320 patent. Case O:98-cv-O7164-A… COMPLAINT for patent infringement filed; FILING FEE $150.00 RECEIPT # 514809; A-7; LSS (Former …quot; _;,_ `-.` w l ~". (.».‘ COMPLA|NT FOR PATENT |NFR|NGEMENT ':p: §§ _,"" r\J External link to document
2004-06-01 274 the manufacturer of NAPROSYN®, owned U.S. Patent 3,998,966, directed to, inter a_lig, Case O:98-cv-O7164…offered to sell the patented invention more than one year prior to filing its patent application and that…application, E|an was issued U.S. Patent 5,637,320 on June 10, 1997. The ’320 patent includes one independent…'320 patent under 35 U.S.C. § 271(e)(2)(A). Andrx defended by arguing that E|an’s patent is invalid… matter of each claim of the patent was complete and ready for patenting at the time of the Lederle |etter External link to document
2009-03-09 326 hereby ordered that: 1. The claims of U.S. Patent No_. 5,637,320 are valid, enforceable and infringed by …1998 11 March 2009 0:98-cv-07164 830 Patent None District Court, S.D. Florida External link to document
2009-03-11 328 enjoined until the expiration of U.S. Patent No. 5,637,320 (“the ‘320 patent”), or final, non- appealable finding… ‘320 patent, or iinal, non~appe_alable finding of invalidity of the claims of the ‘320 patent from manufacturing…Infringing Product prior to the expiration of the ’320 patent, including replacing its Cer`tifications under …1998 11 March 2009 0:98-cv-07164 830 Patent None District Court, S.D. Florida External link to document
1998-11-13 4 States Patent No. 5,637,320; C. declare and adjudge that United States Patent No. 5_,637,320 is invalid…admits that United States Patent No. 5,637,320 (hereinafter "the '320 patent") entitled "…adjudge that United States Patent No. 5,637,320 is unenforceable due to patent misuse; 4 HOULIHAN &…that the '320 patent is unenforceable due to patent misuse. 22. The '320 patent is unenforceable… '320 patent is attached to the Complaint as Exhibit A. Denies that the '320 patent was lawfully External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Baxter
Johnson and Johnson
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.